Article
Folylpolyglutamate synthetase inactivation in relapsed ALL induces a druggable folate metabolic vulnerability.
Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy - 1 Nov 2024
Li Hui, Chen Yao, Ding Ming, Liu Jingjing, Sun Huiying, Fang Houshun, Brady Samuel W, Xu Yan, Glaser Fabian, Ma Xiaotu, Tang Yabin, Du Liang, Wu Xiaoyu, Wang Shuxuan, Zhu Liang, Li Benshang, Shen Shuhong, Zhang Jinghui, Zheng Liang, Yu Jiyang, Assaraf Yehuda G, Zhou Bin-Bing S
Abstract excerpt
AIMS: The antifolate methotrexate (MTX) is an anchor drug used in acute lymphoblastic leukemia (ALL) with poorly understood chemoresistance mechanisms in relapse. Herein we find decreased folate polyglutamylation network activities and inactivating FPGS mutations, both of which could induce MTX resistance and folate metabolic vulnerability in relapsed ALL. METHODS: We utilized integrated systems biology analysis...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
